Last 48 quarters of trend data · Healthcare · Rare Disease Biotech
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.01 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 2.08 | 2.22 | 3.97 | 3.87 | 2.77 | 4.69 | 5.38 | 6.26 | 6.10 | 9.51 | 6.05 | 9.04 | 7.61 | 6.51 | 7.55 | 7.02 | 7.86 | 8.00 | 11.67 | 15.79 | 17.29 |
| — | -52.7% | -26.1% | -38.1% | -54.5% | -50.7% | -11.2% | -30.8% | -19.8% | +45.9% | -19.8% | +28.8% | -3.2% | -18.5% | -35.3% | -55.5% | -54.5% | -57.3% | -37.0% | -17.8% | -29.3% | |
| P/B Ratio | — | — | — | — | — | 185.72 | 22.62 | 23.05 | 15.35 | 14.99 | 8.23 | 28.06 | 14.08 | 80.56 | 25.35 | 12.80 | 9.22 | 6.19 | 6.15 | 6.34 | 6.25 |
| — | — | — | — | — | +1138.8% | +174.8% | -17.8% | +9.0% | -81.4% | -67.5% | +119.2% | +52.8% | +1201.9% | +312.0% | +101.9% | +47.5% | -5.6% | -7.2% | -12.5% | -19.4% | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 83.8% | 81.5% | 84.1% | 77.9% | 86.0% | 82.5% | 86.2% | 79.4% | 89.8% | 84.9% | 85.5% | 83.9% | 90.5% | 88.8% | 90.8% | 87.8% | 94.9% | 90.5% | 90.7% | 92.4% | 95.8% |
| — | -1.2% | -2.4% | -1.9% | -4.2% | -2.9% | +0.8% | -5.3% | -0.9% | -4.4% | -5.9% | -4.5% | -4.5% | -1.9% | +0.1% | -4.9% | -1.0% | -4.6% | -5.9% | -2.5% | +1.9% | |
| Operating Margin | -79.5% | -63.6% | -35.0% | -124.3% | -55.1% | -106.9% | -64.8% | -102.6% | -74.2% | -94.6% | -79.1% | -151.9% | -95.8% | -148.0% | -136.6% | -153.3% | -140.9% | -248.1% | -158.5% | -170.9% | -123.0% |
| — | +40.5% | +45.9% | -21.1% | +25.7% | -12.9% | +18.1% | +32.5% | +22.6% | +36.1% | +42.1% | +0.9% | +32.0% | +40.4% | +13.8% | +10.3% | -14.6% | -125.5% | -66.5% | -59.4% | -17.2% | |
| Net Margin | -85.4% | -68.2% | -43.0% | -136.0% | -62.3% | -112.8% | -69.0% | -108.5% | -80.9% | -95.7% | -89.5% | -156.8% | -96.7% | -162.8% | -147.6% | -163.2% | -146.9% | -270.2% | -177.0% | -190.6% | -146.9% |
| — | +39.5% | +37.7% | -25.4% | +23.0% | -17.9% | +22.9% | +30.8% | +16.3% | +41.2% | +39.3% | +3.9% | +34.2% | +39.7% | +16.6% | +14.4% | -0.0% | -202.2% | -25.8% | -39.1% | -459.9% |
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -607.5% | — | — | — | — | -206.8% | -74.3% | -73.1% | -43.3% | -34.0% | -46.0% | -82.1% | -80.2% | -198.6% | -91.5% | -57.2% | -37.0% | -42.7% | -21.5% | -17.7% | -13.2% |
| — | — | — | — | — | -509.0% | -61.6% | +11.0% | +46.0% | +82.9% | +49.7% | -43.5% | -117.0% | -364.7% | -326.3% | -223.0% | -180.2% | -458.0% | -77.6% | -43.8% | -400.2% | |
| ROA | -37.9% | -9.6% | -7.2% | -13.1% | -9.5% | -14.5% | -8.8% | -10.7% | -8.8% | -8.5% | -9.0% | -12.2% | -9.0% | -12.5% | -11.9% | -11.2% | -9.6% | -16.7% | -11.7% | -10.5% | -8.1% |
| — | +33.4% | +18.1% | -21.9% | -8.1% | -70.9% | +2.4% | +12.0% | +2.9% | +32.5% | +24.2% | -9.0% | +5.9% | +24.9% | -1.4% | -6.8% | -17.8% | -242.4% | -48.6% | -29.2% | -413.5% | |
| ROIC | -89.4% | -11.3% | -7.1% | -16.2% | -11.7% | -35.7% | -178.0% | -112.0% | -50.1% | -87.4% | -301.2% | -142.7% | -165.3% | -372.3% | -102.7% | -55.8% | -60.2% | -50.6% | -17.2% | -15.3% | -10.7% |
| — | +68.4% | +96.0% | +85.5% | +76.6% | +59.1% | +40.9% | +21.5% | +69.7% | +76.5% | -193.1% | -155.9% | -174.7% | -636.2% | -498.6% | -264.3% | -462.1% | -465.8% | -99.6% | -15.5% | +25.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | 54.76 | 0.23 | 0.25 | 0.15 | 0.10 | 0.09 | 0.29 | 0.16 | 1.47 | 0.20 | 0.13 | 0.09 | 0.07 | 0.06 | 0.05 | 0.05 |
| — | — | — | — | — | +56747.5% | +164.7% | -12.9% | -1.9% | -93.4% | -56.6% | +124.0% | +74.9% | +1887.1% | +260.2% | +162.4% | +97.0% | +56.8% | +16.6% | +13.0% | +8.9% | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 2.48 | 1.40 | 1.73 | 2.02 | 2.48 | 1.89 | 2.45 | 2.40 | 2.37 | 2.81 | 3.54 | 2.43 | 2.61 | 2.36 | 2.87 | 3.51 | 3.38 | 4.45 | 3.08 | 4.23 | 4.72 |
| — | -26.1% | -29.7% | -15.7% | +4.3% | -32.6% | -30.6% | -1.2% | -9.1% | +18.9% | +23.0% | -30.9% | -22.8% | -47.0% | -6.6% | -17.0% | -28.4% | -28.5% | -58.8% | -49.8% | -30.9% | |
| Quick Ratio | 2.34 | 1.25 | 1.56 | 1.85 | 2.34 | 1.74 | 2.30 | 2.24 | 2.24 | 2.65 | 3.39 | 2.28 | 2.49 | 2.23 | 2.76 | 3.39 | 3.28 | 4.36 | 2.98 | 4.12 | 4.63 |
| — | -28.3% | -32.1% | -17.3% | +4.4% | -34.5% | -32.2% | -1.8% | -9.9% | +18.8% | +22.9% | -32.7% | -24.1% | -48.7% | -7.5% | -17.8% | -29.2% | -28.8% | -59.5% | -50.5% | -31.5% | |
| Interest Coverage | -8.21 | -5.50 | -3.14 | -7.76 | -5.74 | -11.69 | -7.12 | -9.44 | -7.59 | -7.48 | -7.19 | -9.74 | -6.32 | -8.00 | -9.35 | -9.46 | -8.66 | -15.46 | -25.08 | -22.05 | -31.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying RARE stock.
Ultragenyx Pharmaceutical Inc.'s current P/E is -3.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Ultragenyx Pharmaceutical Inc.'s current operating margin is -79.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Ultragenyx Pharmaceutical Inc.'s business trajectory between earnings reports.